NEW HIGHLIGHT
Blenrep

Blenrep

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
Concise Prescribing Info
Contents
Belantamab mafodotin
Indications/Uses
Monotherapy for the treatment of multiple myeloma in adults, who have received at least 4 prior therapies & whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, & an anti-CD38 monoclonal Ab, & who have demonstrated disease progression on the last therapy.
Dosage/Direction for Use
IV 2.5 mg/kg infused over 30 min once every 3 wk.
Contraindications
Special Precautions
Reports of corneal adverse reactions. Perform ophth examination (including visual acuity & slit lamp examination) at baseline, before the subsequent 3 treatment cycles, & as clinically indicated during treatment. Administer preservative-free artificial tears at least 4 times daily beginning on the 1st day of infusion & continuing until completion of treatment to reduce corneal symptoms. Avoid using contact lenses until the end of treatment. Reports of thrombocytopenic events. Obtain complete blood counts at baseline & monitor during treatment, as clinically indicated. Reports of infusion-related reactions. Moderate influence on the ability to drive or use machines. Patients w/ severe renal impairment. Patients w/ moderate or severe hepatic impairment. May impair fertility in females & males of reproductive potential. Women of child-bearing potential should use effective contraception during treatment & for 4 mth after the last dose. Men w/ female partners of child-bearing potential should use effective contraception during treatment & for 6 mth after the last dose. Pregnancy. Discontinue breast-feeding prior to initiating treatment & for 3 mth after the last dose. Childn & adolescents <18 yr. Patients w/ body wt <40 or >130 kg.
Adverse Reactions
Pneumonia; thrombocytopenia, anaemia, lymphopenia, leukopenia, neutropenia; keratopathy, blurred vision events, dry eye events; nausea, diarrhoea; pyrexia, fatigue; increased AST & γ-glutamyltransferase; infusion-related reactions. Upper resp tract infection; photophobia, eye irritation; vomiting; increased creatine phosphokinase.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FX15 - belantamab mafodotin ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.
Presentation/Packing
Form
Blenrep powd for concentrate for soln for infusion 100 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in